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Visceral leishmaniasis (VL) caused by Leishmania donovani and Leishmania infan-
tum/chagasi represents the secondmost challenging infectious diseaseworldwide, leading
to nearly 500,000 new cases and 60,000 deaths annually. Zoonotic VL caused by L. infan-
tum is a re-emergent canid zoonoses which represents a complex epidemiological cycle
in the New world where domestic dogs serve as a reservoir host responsible for poten-
tially fatal human infection and where dog culling is the only measure for reservoir control.
Life-long immunity to VL has motivated development of prophylactic vaccines against the
disease but very few have progressed beyond the experimental stage. No licensed vaccine
is available till date against any form of leishmaniasis. High toxicity and increasing resis-
tance to the current chemotherapeutic regimens have further complicated the situation in
VL endemic regions of the world. Advances in vaccinology, including recombinant proteins,
novel antigen-delivery systems/adjuvants, heterologous prime-boost regimens and strate-
gies for intracellular antigen presentation, have contributed to recent advances in vaccine
development againstVL. Attempts to develop an effective vaccine for use in domestic dogs
in areas of canine VL should be pursued for preventing human infection. Studies in animal
models and human patients have revealed the pathogenic mechanisms of disease pro-
gression and features of protective immunity.This review will summarize the accumulated
knowledge of pathogenesis, immune response, and prerequisites for protective immunity
against humanVL. Authors will discuss promising vaccine candidates, their developmental
status and future prospects in a quest for rational vaccine development against the disease.
In addition, several challenges such as safety issues, renewed and coordinated commit-
ment to basic research, preclinical studies and trial design will be addressed to overcome
the problems faced in developing prophylactic strategies for protection against this lethal
infection.
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INTRODUCTION
Leishmaniases are a wide spectrum of parasitic diseases caused by
dimorphic protozoan flagellates of the genus Leishmania. These
obligatory parasites of host macrophages are transmitted by ∼30
different species of phlebotomine sandflies (Pearson and Sousa,
1996). Leishmaniasis accounts for global morbidity of 2.4 millions
(946,000 for males and 1,410,000 for females) and a mortality rate
of approximately 60,000 per year1. Among the three clinical pat-
terns of leishmaniasis (cutaneous, mucocutaneous, and visceral),
visceral leishmaniasis (VL) is the most severe in terms of symp-
toms and clinical complications. Of the 500,000 new cases of VL
every year, 90% occur in Bangladesh, Brazil, India, Ethiopia,Kenya
and Sudan, countries that are strongly related to poverty (Hotez
et al., 2004; Alvar et al., 2006). India alone accounts for more than
half of the annual global VL infections, which is rapidly emerging
as an important opportunistic HIV-coinfection.
Based on transmission characteristics, there are two types ofVL:
zoonotic VL caused by Leishmania infantum, and anthroponotic
VL or kala-azar caused by Leishmania donovani. Kala-azar is
1http://www.who.int/tdr/disease/leish/direction.htm
a systemic infection clinically characterized by prolonged fever,
profound cachexia, hepatosplenomegaly, hypergammaglobuline-
mia, and pancytopenia, with an incubation period varying
between 2 and 6 months (Bray, 1976; Chappuis et al., 2007).
Almost all clinically symptomatic patients die within months if
left untreated. Moreover, 5–10% of cured individuals from VL
in India and 50% in Sudan may also develop cutaneous mani-
festations in the form of macular, maculo-papular, and nodular
skin lesions containing parasites, termed as post-kala-azar dermal
leishmaniasis (PKDL). PKDL represents an important yet unclear
issue of parasite persistence and the putative reservoir for kala-
azar between epidemic cycles that need special attention for VL
eradication (Addy and Nandy, 1992; Dereure et al., 2003).
In India the few therapeutic options registered for kala-azar
include pentavalent antimonials (sodium stibogluconate), liposo-
mal/free amphotericin B, miltefosine, and paromomycin. How-
ever, all have one or more limitations or insufficiencies in the
long run. Growing resistance to pentavalent antimonials, prohib-
itive cost of the available lipid formulations of amphotericin B,
toxicity, need for hospitalization, HIV-coinfection, and increasing
reports of relapse, have made the global demand for VL vac-
cine a major public health priority. Life-long immunity against
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reinfection indicates feasibility of successful vaccination against
VL. However, no anti-leishmanial vaccine is still available for
human use. Considerable inter-specific diversity of lipophospho-
glycan (LPG) structure, extraordinary host evasive mechanism of
the parasite and heterogeneity of human population (Beverley and
Turco, 1998; Kaye and Scott, 2011) represent unprecedented chal-
lenges for VL vaccinology. Absence of an in vivo animal model
accurately reflecting the clinical features of human VL adds to
limitations of development of immunoprophylaxis against VL.
However, current advances in genome sequencing and biotech-
nology have created a thrust for VL vaccinology an area which
has been neglected for years. Development of a cross-protective
anti-Leishmania vaccine is thus a desirable public health goal to
combat this lethal infection.
Till date vaccine research against VL can be divided into three
main groups: vaccinationwith live virulent or killed parasites (first
generation vaccines), vaccination with whole-cell lysates/purified
fractions, subunit vaccination with native/recombinant parasite
proteins (second-generation vaccines), andplasmidDNAandviral
vector based vaccines encoding parasite virulence factors (third
generation vaccines). Recent concepts include use of genetically
modified live-attenuated Leishmania parasites, and proteomics
approach for the search of a cross-protective leishmanial vaccine
that would ideally protect against both cutaneous and visceral
forms of the disease.
IMMUNOPATHOLOGY OF HUMAN VL: IMPLICATIONS FOR
VACCINE DESIGN
The clinical manifestations of leishmaniasis are determined not
only by the parasite species but also by the general health and
genetic constitution of the host (Bogdan et al., 1996; D’Oliveira
Júnior et al., 1997). Understanding the immunological changes
that are associated with resistance and susceptibility to the disease
are fundamental to both designing as well as evaluating outcome
of vaccines. Although mouse models have been used for study of
both cutaneous and VL, very little is known about human VL.
Clinical studies reveal that humanVL has a complex immunol-
ogy characterized by mixed T-helper-1 (Th1)/T-helper-2 (Th2)
cell milieu, where a suppressed Th1 response along with an ele-
vated Th2 is the hallmark of the active disease. Conversely, pro-
tective immunity is achieved by upregulation of Th1 response
after a successful chemotherapy (Hailu et al., 2001; Kubar and
Fragaki, 2005). The crucial step in generating anti-leishmanial
immunity is maintenance of the proportion of CD4+ and CD8+
T cells that results in secretion of different cytokines required
for immunomodulation in VL. Patients with kala-azar demon-
strate negative delayed type hypersensitivity and non-proliferative
response to parasite antigens (Sacks et al., 1987; Dominguez et al.,
2002). Most of the T cell clones from the PBMCs of the active
VL patients and asymptomatic subjects (seropositive and DTH
positive) are CD8+ with negligible CD4+, while the situation is
reversed in the cured individuals with more numbers of CD4+
than CD8+ cells (Saha et al., 2006). Probably, the CD4+ T cells are
lost prior to CD8+ cells in VL, thus a depressed CD4:CD8 ratio
has been observed in patients compared with controls (Rohtagi
et al., 1996; Clarêncio et al., 2009). Associated upregulation of
immunosuppressive CD4+CD25+ regulatory T cells (Treg) in
active VL patients probably leads to parasite persistence and
chronic infection (Saha et al., 2007).
Cellular immunity is considered to be the keymediator of resis-
tance by means of IFN-γ that induces microbicidal activity against
both the promastigotes and amastigote forms of L. donovani, in an
H2O2-dependent (Murray and Cartelli, 1983; Murray et al., 1983)
and NO-mediated pathway (Vouldoukis et al., 1997) for parasite
clearance (Badaro et al., 1990; Badaro and Johnson, 1993; Harms
et al., 1993; Squires et al., 1993; Sundar et al., 1994, 1995, 1997a,b;
Sundar and Murray, 1995). Probably, impaired macrophage func-
tions due to lack of detectable inducible NO synthase mRNA
activity in liver and spleen fastens the disease progression in L.
donovani infected hamsters, closely resembling the situation in
human VL (Melby et al., 2001a). IL-12 is an immunoregulatory
cytokine for initiation and maintenance of the Th1 response and
plays an important role in the induction of IFN-γ production by
T and NK cells (Kobayashi et al., 1989; Stern et al., 1990; Scharton
and Scott, 1993; Trinchieri, 1993). In VL patients, IL-12 enhances
Th1 responses and restores lymphocyte proliferative responses,
IFN-γ production and cytotoxic responses (Ghalib et al., 1995;
Bacellar et al., 1996). TNF-α is a proinflammatory chemokine
associatedwith bothprotection and susceptibility to leishmaniasis.
When produced at very high levels, TNF-α might have a disease-
enhancing effect (Karplus et al., 2002). IL-4, considered to be a
marker of Th2 response, is present in the sera, PBMC supernatant
(Zwingenberger et al., 1990; Sundar et al., 1997a) and as mRNA
in active VL (Carvalho et al., 1994; Kenney et al., 1998). Although
largely implicated in disease exacerbation (Zwingenberger et al.,
1990), beneficial role of IL-4 in driving Th1 immunity for early
protection against VL has also been suggested (Kamogawa et al.,
1993; Alexander et al., 2000). IL-10 primarily down-modulates
innate as well as acquired immune response. Moreover, IL-10
induction by host IgG-opsonized amastigotes leads to immune
suppression of Th1 response with downregulation of IL-12 for
disease progression (Caldas et al., 2005). Patients with VL have
increased expression of mRNA for IL-10 in bone marrow and
lymph nodes with enhanced levels of IL-10 in sera and leishmanial
antigen-stimulated PBMC supernatants (Saha et al., 2007). Imbal-
anced IL-10 production may be associated with disease progres-
sion to PKDL (Ghalib et al., 1993; Saha et al., 2007). Transforming
growth factor-β (TGF-β) having immunosuppressive properties, is
also documented in leishmaniasis disease progression (Nylén and
Akuffo, 2009; Donaghy et al., 2010). A high level of total TGF-β
affects NO production by deactivating macrophages both in vitro
and in vivo (Barral-Netto et al., 1992; Li et al., 1999). Recent stud-
ies have linked IL-13 (Babaloo et al., 2001), IL-15 (Carson et al.,
1994, 1995; Armitage et al., 1995; Jullien et al., 1997; Milano et al.,
2002), IL-17 and IL-22 (Pitta et al., 2009)with protection against L.
donovani. IL-27, produced mainly by macrophages and DC, regu-
lates Th17 cells thereby maintaining a balance between immunity
and pathology in human VL (Anderson et al., 2009; Murugaiyan
et al., 2009). Enhanced IL-27 in VL patients is shown to induce
IL-21 which in turn promotes expansion of IL-10 secreting T
cells, leading to parasite multiplication in spleen (Ansari et al.,
2011).
Together with phagocytes, NK cells represent the first line of
defense against pathogens by two principal mechanisms, cytolytic
Frontiers in Immunology | Microbial Immunology May 2012 | Volume 3 | Article 99 | 2
Das and Ali Vaccination against visceral leishmaniasis
destruction of infected cells, and secretion of proinflammatory
cytokines (e.g., IFNγ, TNFα; Nylén et al., 2003). Activated NK
cells promote DC maturation along with clearance of autologous
immatureDCs (Akuffo et al., 1993; Piccioli et al., 2002). Compara-
tively lower frequency of NKcells in activeVL than controls further
confirms their role in healing (Nylén et al., 2007). Conversely, DCs
are pivotal in initiating and orchestrating the immune response
by phagocytosis, antigen presentation, and cytokine production
(Banchereau and Steinman, 1998; Mellman and Steinman, 2001).
DCs essentially guide resistance or susceptibility to Leishmania
by driving the differentiation and proliferation of CD4+ T cells
toward one of the two polarized pathogen-specific Th1 or Th2
phenotype (Moser and Murphy, 2000). Differential roles of DC–
NK cell cross-talk at various stages of Leishmania infection present
new insight on the interactions between innate immune compo-
nents during infection with this parasite (Sanabria et al., 2008).
Exploitation of DC biology may thus be a rationale of VL vaccine
design for better antigen-delivery and presentation.
Although elevated levels of anti-leishmanial antibodies IgG,
IgM, IgE, and IgG subclasses are well documented in active VL
(Atta et al., 1998; Anam et al., 1999a,b; da Matta et al., 2000; Ryan
et al., 2002; Ravindran et al., 2004), their precise role in protection
against Leishmania is controversial and needs to be reappraised.
IFN-γ probably upregulates IgG1 and IgG3, while IL-4 and IL-
5 stimulate the production of high levels of IgG, IgM, IgE, and
IgG subclasses like IgG4 in humans (Ozbilge et al., 2006). How-
ever, antibodies are not relevant for vaccine-induced protection
in the absence of an appropriate cellular response. Overall, both
CD4+ and CD8+ T cells are required to mediate parasite control
and successful vaccination requires IL-12 driven IFN-γ-dependent
Th1/Th2mixed response againstVL.However,high IL-4 and IL-10
production in immunized animals, despite very high IFN-γ, may
lead to vaccine failure and disease exacerbation in VL (Bhowmick
et al., unpublished data).
COMPLEXITY OF HOST–PARASITE INTERACTION
Leishmania spp. had been widely regarded as fastidious, oblig-
ate intracellular pathogens primarily inhabiting macrophages. But
recent studies have confirmed their presence in hematopoietic
cells having a common myeloid precursor (i.e., neutrophils, resi-
dent macrophages, dermal DCs, inflammatory monocyte-derived
DCs) (Gueirard et al., 2008) and non-hematopoietic cells such
as fibroblasts. Survival of Leishmania within the mammalian
host depends on its ability to evade and manipulate the anti-
leishmanial immune response to establish infection (Bogdan and
Rollinghoff, 1998). Despite the presentation of leishmanial anti-
gens and the initiation of inflammatory responses, Leishmania
can reside within the host tissues for long periods of time by
exploiting several evasive mechanisms (Zambrano-Villa et al.,
2002). Opsonization of Leishmania promastigotes with parasite-
specific IgG facilitates their uptake bymacrophages andDCswhich
leads to establishment of infection (Prina et al., 2004). IL-12 pro-
duced by parasite-engulfed DCs, as a signature of anti-Leishmania
protective response, is counteracted by immunosuppressive IL-10
produced by parasitized macrophages that activates host Treg cells
leading to disease progression (Woelbing et al., 2006). Notably
LPG, the most abundant molecule constituting the glycocalyx
of Leishmania promastigotes, plays an important role in the
interactions between the parasite and the sandfly promoting the
infectivity of the parasites. Considerable diversity in LPG structure
among different Leishmania spp. explains their vector specificity
(Sacks, 2001) and may also affect their immunological properties.
Thus, LPG which is a virulence factor allowing safe passage and
survival of metacyclic promastigotes in macrophages in L. major
(Späth et al., 2000) and L. donovani (Desjardins and Descoteaux,
1997; Lodge et al., 2006; Vinet et al., 2009), has no such role in L.
mexicana (Ilg, 2000). Profound differences in the virulence factors
of L. major and L. donovani also affect their consequent patholo-
gies as well as underlying immune evasive mechanisms, making
development of a cross-protective vaccine difficult. Sandfly saliva
itself can also act as a virulence factor by enhancing invasion of
macrophages by promastigotes, even with low-dose inoculations
(Gillespie et al., 2000). In fact, Leishmania has evolved numerous
strategies to interfere with a broad range of macrophage signal-
ing that includes protein kinase C, the JAK2/STAT1 cascade, and
the MAP kinase pathway that favor its survival and persistence
in host cells (Shadab and Ali, 2011). Recruitment of inhibitory
CD4+CD25+FoxP3+ regulatory T cells (Treg) (Engwerda et al.,
2004; Peters and Sacks, 2006; Nylén et al., 2007), inhibition of
macrophage phagosomal maturation (interfering with fusion of
phagosomes and lysosomes) (Olivier et al., 2005), and inhibition
of DC maturation and chemotaxis (Brandonisio et al., 2004) are
some of the strategies employed by Leishmania to evade effector
mechanisms of the host immune system. Maturation of human
monocyte-derived DCs is inhibited by both L. donovani and L.
amazonensis (Favali et al., 2007; Tejle et al., 2008). Further, deple-
tion of CD8+ T-cell following infection with L. donovani may
contribute to chronic infection (Joshi et al., 2009). Thus, the
main goal of Leishmania vaccinology is establishment of a Th1-
dominated cell-mediated response along with CD8+ T cells for
sustained protective immunity (Scott, 2003).
Though it is often assumed that the type of disease depends
solely on Leishmania species, susceptibility or resistance to leish-
maniasis markedly varies within and between genetically diverse
human populations (Walton and Valverde, 1979; Momeni and
Aminjavaheri, 1994; Weigle and Saravia, 1996; Sharma et al.,
2000; Bucheton et al., 2002). For example, PKDL is influenced
by genetic polymorphism in IFN-γ receptor (Mohamed et al.,
2003), and susceptibility is linked to polymorphism in IL-4 gene
in Sudanese patients (Blackwell et al., 2005). Natural resistance-
associated macrophage protein-1 (NRAMP1) has been shown to
increase the risk of acquiring infection. In mice, Nramp1/Slc11a1
Lsh locus on chromosome 1 is responsible for acute susceptibility
to L. donovani (Demant et al., 1996). However, its role in human
is not clear. This difference is probably due to the fact that the
Lsh/Nramp1/Slc11a1 allele in susceptible mice practically abol-
ishes the gene function (equivalent to a traditional knockout),
whereas polymorphisms in the promoter, exon 3 and the intron of
human SLC11A1 are expected to have less influence on susceptibil-
ity to L. donovani (Bucheton et al., 2003; Mohamed et al., 2004).
Polymorphisms in genes coding HLA class I and class II mole-
cules have been relatedwith susceptibility to L. guyanensis (Barbier
et al., 1987) and L. braziliensis (Lara et al., 1991; Petzl-Erler et al.,
1991) although impact of these polymorphisms on VL species
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seems ambiguous (Bucheton et al., 2003). Recent genome-wide
linkage study from Sudan and Brazil has identified a putative sus-
ceptibility locus DLL1 (Delta-like 1 for Notch3) which is strongly
implicated as the chromosome 6q27 VL susceptibility gene (Faki-
ola et al., 2011). In brief, further understanding of the complex yet
unique species-specific virulence mechanisms, immunogenetics,
and clinical correlates is needed for early diagnosis, customized
chemotherapeutic strategies, and prophylaxis against VL.
PROGRAMMING OF INNATE IMMUNITY
The role of innate immune system comprising of macrophages,
DCs, NK cells, and granulocytes forming the primary defense
mechanism against pathogen, is gaining increasing attention in
curingVL. Innate immune system is activated via pattern recogni-
tion receptors (PRRs) on host macrophages and DCs that recog-
nize conserved pathogen-associated molecular patterns (PAMPs)
of microbes. Activation of PRRs like Toll-like receptors (TLRs),
nucleotide-binding domain (NOD)-like receptors and scavenger
receptors by PAMPs leads tomaturation and trafficking of theDCs
to local lymph nodes for antigen presentation to naive T cells rais-
ing the adaptive immunity against the invading pathogen (Kaisho
and Akira, 2000, 2001; Bocarsly et al., 2002). Again the pattern of
TLR expression varies between the APC subsets and their anatom-
ical locations (Banchereau and Steinman, 1998). Secretion of
proinflammatory cytokines and chemokines following TLR acti-
vation contribute to Th1-independent immediate defense mecha-
nisms (Hayashi et al., 2003). Bypassing these natural innatemecha-
nisms by Leishmania promastigotes probably marks the beginning
of successful parasitism. Leishmania adopts apparently quiescent
mechanisms of macrophage entry with slow or negligible stimula-
tion of NF-κβ pathway which appears to be true for all Leishmania
spp., thus delaying adaptive response. This has been experimen-
tally evidenced in mice receiving low-dose parasite challenge in
the ear (Belkaid et al., 2000). Plethora of evidence suggests a cru-
cial role of TLR:PAMP interaction for bridging innate and adaptive
immunity. Past experiencewith vaccine success of leishmanization
(consisting of live virulent parasites) as against reduced protec-
tion by killed vaccines can possibly be assumed due to loss of
parasite PAMPs during inactivation process which is required for
establishing future adaptive immunity. To alleviate this problem,
subunit or genetic vaccines are often adjuvantedwithTLR-agonists
for innate triggering of adaptive immunity to elicit robust cel-
lular and humoral response. TLR ligands that mimic PAMPs to
activate immune cells via Toll-like receptors (TLRs) are being
developed for clinical use and immunotherapy against a variety
of diseases. Adjuvant success of several TLR-agonists like CpG-
DNA (immunostimulatory oligodeoxynucleotides):TLR9 agonist,
MPL (Monophosphoryl Lipid) A and GLA (Glucopyranosyl Lipid
Adjuvant): TLR4 agonists, and imiquimod: TLR7 agonist, have
been well documented against Leishmania (Buates and Mat-
lashewski, 1999; Walker et al., 1999; Reed et al., 2003; Coler et al.,
2007). Synthetic imidazoquinoline compounds (i.e., imiquimod
and resiquimod) have been shown to activate human TLR7 and
8 (Gibson et al., 2002; Hemmi et al., 2002), and TLR7 in mice.
TLR3 and TLR4 in synergy with TLR7, TLR8, and TLR9 in human
and mouse DCs boost up Th1 response through increased pro-
duction of IL-12 and IL-23. TLR synergy further establish DCs
unidirectional intracellular cross-talk to acquire T cell response to
a given vaccine in MyD88-dependent manner (Kang et al., 2002;
Martinon and Tschopp, 2005; Napolitani et al., 2005; Zhu et al.,
2008). Combinatorial synergy of MPL with CpG in L110f vaccine
has shown to improve immunotherapy against murine CL proba-
bly resulting from chemokineRANTES (regulated upon activation
normal T cell expressed and secreted) expression thereby recruit-
ing activated T cells to the site of infection with enhanced IL-12
production (Raman et al., 2010). Future vaccination strategies
using live non-virulent or genetically altered parasites with TLR
7/8 or TLR 4 agonists can be appropriate combination for prim-
ing innate immunity for durable, broad spectrum cross-protection
against Leishmania. Designing of such novel multicomponent
adjuvants combining TLRs and/or non-TLRs with vaccines for
better amplification of T-cell and B-cell response merits further
study.
ANIMAL MODELS FOR VL
Among several models tried for L. donovani, BALB/c mice and
Syrian golden hamsters (Mesocricetus auratus) are the most exten-
sively studied animalmodels for primary screening of vaccines and
drugs.Absenceof functionalSc11 1a1 locus inBALB/c andC57BL6
mice renders them susceptible to L. donovani infection compared
to resistant CBA mice possessing functional Sc11 1a1gene that
confers innate anti-leishmanial immunity (Bradley, 1974; Black-
well, 1996). Unlike L. major infection, Th1/Th2 dichotomy in
cytokine milieu is not evident during murine VL caused by L.
donovani/chagasi. The protective immunity in murineVL primar-
ily depends on IL-12 driven Th1 response leading to increased IL-2
and IFN-γ production for parasite killing. Substantial upregula-
tion of inducible NO synthase (iNOS, NOS2) by IFN-γ generates
NO from splenic and liver macrophages thereby controlling par-
asite multiplication in these organs (Green et al., 1990; Blackwell,
1996). TGF-β, IL-10, and IL-13 are the major disease promoting
cytokines leading to suppression of Th1 response (Wilson et al.,
2005). Low levels of IL-4 usually enhance vaccine-induced protec-
tion by increasing IFN-γ production from CD8+ T cells (Stäger
et al., 2003) and subsequently play no role in disease exacerbation
in L. donovani infected mice. Despite the wide usage of the mouse
model for vaccine studies inVL, this does not resemble the clinical
outcomes seen in fatal human VL. Murine VL is largely subclin-
ical and self-resolving disease compared to disseminated visceral
infectionwhich seems to be a major limitation in extrapolating the
results to humanVL. In mice, clearance of hepatic parasite burden
occurs after 2 weeks post infection due to efficient granuloma for-
mation resulting from interaction of Leishmania-specific T cells
with parasitized dendritic cells and resident macrophages. Parasite
killing in mature granulomas leads to resolution of hepatic infec-
tion in about 56 days in experimental VL. Hence, vaccine efficacy
and disease progression in mice can be predicted from the degree
of maturation of hepatic granulomas in challenged animals corre-
lating with cell-mediated immunity (Murray et al., 1992; Carrión
et al., 2006). In contrast to liver, spleen, and bonemarrow act as the
site of parasite persistence resulting in chronic infection in mice.
The failure of parasitized marginal zone macrophages of spleen to
produce IL-12,breakdownof splenic architecture and lack of gran-
ulomatous reaction leads to high parasite burden in spleen (Nieto
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et al., 2011). Infecting mice with large inoculums can thus be more
suitable to resemble pathological changes similar to active human
VL (Carrión et al., 2006). Interestingly, inoculating BALB/c mice
with Indian L. donovani strains like AG83 leads to progressive VL
with clinical manifestations of hepatosplenomegaly, at least up to
6 months post infection (Mazumder et al., 2004; Bhowmick et al.,
2009). The disease progression in this model is associated with
suppressed Th1 response due reduced IFN-γ and IL-12 produc-
tion from spleen cells along with enhanced IL-4 and IL-10, which
get reversed with vaccine-induced protection. Further, infected
mice also demonstrate high TGF-β and low TNF-α 4 months post
infection resulting in impairedNO-mediated parasite clearance by
macrophages (Bhowmick et al., 2009). However, precise correlates
of pathology and protection are yet to be defined for this model
for development of successful intervention against human VL.
Compared to mice, hamsters seem to a better model for pro-
gressive VL expressing clinical features like hepatosplenomegaly,
immunosuppression, anemia, cachexia, and death, closely simu-
lating human VL. Impaired macrophage activation in liver and
spleen due to lack of NOS2 expression throughout disease pro-
gression seems to be the major cause of uncontrolled parasite
multiplication and death in hamster (Melby et al., 2001a). High
levels of TGF-β have also been reported in tissues and cultured
immune cells from mice and hamsters infected with L. donovani
and L. chagasi, suggesting its definitive role in disease exacerba-
tion (Müller et al., 1992; Gomes et al., 2000; Gantt et al., 2003).
Increased secretion of TNF-αduring later stage of disease probably
results in profound weight loss in infected hamsters (Tracey et al.,
1988). However, inadequacy of immunological reagents limits the
use of hamster model for prophylactic and therapeutic analy-
sis of VL. High innate susceptibility of hamsters to L. donovani
makes them a more suitable model for studying immunopathol-
ogy of VL than evaluation of protective immunity. Among several
higher non-human primate models of VL, Indian langur mon-
key (Presbytis entellus) has shown consistent and progressive VL
similar to active human disease. Immune protection achieved by
autoclavedL. donovani (ALD) alongwithBCG in thismodel corre-
lates with high IFN-γ, IL-2, and lymphoproliferation (Dube et al.,
1998; Misra et al., 2001). Difficulties in laboratory handling, non-
availability and expense are some of the drawbacks of primate
models that need to be solved for their routine use as VL models.
VL VACCINE DEVELOPMENT: CONVENTIONAL APPROACHES
FIRST GENERATION VACCINES
“Leishmanization,” the traditional practise of inoculating live, vir-
ulent Leishmania parasites from the exudates of a cutaneous lesion
is the only successful intervention against leishmaniasis and has
been practiced for centuries in Middle East and Russia with effi-
cacy levels up to 100% (Nadim et al., 1983; Khamesipour et al.,
2005). Based on persistence of parasites in the primary inoculated
site for cellular response, leishmanization could confer virtually
life-long and complete protection which is of utmost importance
for developing anti-leishmanial vaccine. Unfortunately, features
of adaptive immunity elicited for successful leishmanization have
not been studied in human. It is known that previous exposure
to L. major can confer protection against subsequent VL (Zijlstra
et al., 1994). However, leishmanization trials have never been done
either against New World tegumentary leishmaniasis or human
VL. Although still practiced in Uzbekistan, severe side effects
and complications have eventually replaced it by first generation
killed Leishmania vaccines, with or without adjuvants. In order to
improve safety of leishmanization, live L. major have been coin-
jectedwithCpG-DNAwithout compromising the vaccine potency
inmurinemodel (Mendez et al., 2003). Success of CpG adjuvanted
live vaccine in murine CL apparently depended on CD4 Th17 cells
and early recruitment of IFN-γ secreting CD4 cells at inoculation
site for long-term protection (Wu et al., 2010). This vaccine also
resulted in activation of dermal DCs and NK cells for enhanced
protection almost without any side effect unlike leishmanization.
Although effective against VL in several experimental models,
recent human clinical trials of killed vaccines have been found to
be safe but not as effective as leishmanization, having low efficacies
(54%) when tested in humans (Sharifi et al., 1998; Momeni et al.,
1999; Armijos et al., 2004; Vélez et al., 2005) and dogs (Genaro
et al., 1996; Mohebali et al., 2004). The success of leishmanization
over killed vaccines in CL can possibly be explained by an in vitro
study evaluating human T cell function when simulated by live
vs. killed parasites (Nateghi Rostami et al., 2010). In addition to
increased IFN-γ from CD4+ T cells, live parasites could also stim-
ulate CD8+ T cells to secrete IFN-γ. Killed parasites, however,
could stimulate CD4+ T cells only. This probably accounts for
better immunologic memory leading to sustained immunity after
healing of live infections (Okwor and Uzonna, 2008; Nateghi Ros-
tami et al., 2010). Promising enough, a very recent approach have
generated a killed butmetabolically active L. infantum chagasi pro-
mastigotes after treating them with amotosalen and low-dose UV
radiation that resulted in replication-deficient parasites that could
protect mice against experimental VL (Bruhn et al., 2012). These
parasite could enter host macrophages for initial transformation
for stimulating robust adaptive immunity for protection lasting
up to 6 weeks post infection. However, most clinical trials have
been conducted for CL with very few for VL (Khalil et al., 2000,
2006). The anticipated success with CL clinical trials may lead to a
few human VL trials due to the highly conserved genomes of the
Leishmania spp.
Ease of production, economy, and safety of first generation
leishmanial vaccines have made them attractive for immunother-
apeutic strategy against VL. Combination therapy comprising of
alum-precipitated autoclaved L. major (ALM) with BCG has been
found to be protective in PKDL patients significantly reducing
cases of relapse (Musa et al., 2008). Killed Leishmania vaccines
probably hold more prospects for immunotherapy combined with
drugs than their single use against VL which needs further human
trials.
SECOND-GENERATION VACCINES
Vaccination with Leishmania fractions
Partially or fully purified Leishmania subfractions have been
widely used in experimental models (Gradoni, 2001; Handman,
2001) owing to their excellent immunoprotective properties. Pre-
vious studies showed that vaccinationwith fucose-mannose ligand
(FML) protects against experimental VL in several animal mod-
els such as mice (Swiss Albino and BALB/c) and dog (Palatnik de
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Sousa et al., 1996; Santos et al., 1999, 2002; Parra et al., 2007).Addi-
tionally, membrane antigens of L. donovani promastigotes (LAg)
entrapped in cationic liposomes could induce significant levels of
protection inmice andhamsters (Afrin andAli,1997;Ali andAfrin,
1997; Afrin et al., 2000, 2002). Soluble leishmanial antigen (SLA)
partially purified fraction from LAg, entrapped in cationic lipo-
somes show both prophylactic and therapeutic efficacy against VL
(Bhowmick et al., 2007). Moreover, immunostimulatory sequence
bearing non-coding plasmid DNA co-entrapped in liposomal SLA
showed Th1 biased immune protection in BALB/c mice model
of VL (Mazumder et al., 2007). Recently, fraction (F2) of L.
donovani soluble promastigote antigen belonging to 97.4–68 kDa
has been identified for its ability to stimulate Th1-type cellular
responses in cured VL patients and hamsters (Garg et al., 2006).
Further fractionation of this F2-fraction revealed Th1-stimulatory
polyproteins ranging from 89.9 to 97.1 kDa that could offer long-
lasting protection against L. donovani in hamsters (Kumari et al.,
2008a,b). However, difficulties in large-scale production, stan-
dardization of in vitro culture conditions and purification pro-
cedures are some of the issues raised regarding such vaccines to be
considered for clinical trials against VL.
Subunit protein vaccines
Following hundreds of native and recombinant antigens tested
inducing protection against CL, several molecularly defined vac-
cine candidates have been evaluated against VL over the past two
decades (Table 1). LPG was the first molecularly defined vaccine
candidate against leishmaniasis that conferred protection against
CL (Handman andMitchell, 1985;McConville et al., 1987;Karanja
et al., 2011). Concurrent studies with L. donovani-derived LPG
suggested it as a promising candidate vaccine for transmission
blocking (Tonui et al., 2001). The first recombinant antigen against
leishmaniasis was gp63 or leishmanolysin, conserved in all Leish-
mania species. Although highly protective in its native form, both
against CL (Kahl et al., 1990) and VL (Bhowmick et al., 2008),
recombinant gp63 (rgp63) expressed in E. coli system failed to
induce protection againstCL (Handman et al., 1990).However, the
reports remained controversial since BCG expressing gp63 showed
protection in susceptible mice against L. major challenge (Abdel-
hak et al., 1995) which revealed that immunogenicity of processed
peptides is not likely dependent upon its native structure. Addi-
tionally, recent reports of protection elicited by liposomal delivery
of rgp63 via subcutaneous route, both against L. major (Jaafari
et al., 2006, 2007) and L. donovani (Mazumder et al., 2011b)
validate the use of liposomes as a critical parameter in these vacci-
nation protocols. The high level of similarity in conserved residues
of GP63 among differentVL species: L. donovoni,L. chagasi, and L.
infantum has recently been authenticatedwhich suggests feasibility
of a GP63-based vaccine success against VL (Sinha et al., 2011).
Nuclear histone protein H2B is another highly conserved anti-
gen that is antigenic in several Leishmania species (Soto et al.,
1999; Chenik et al., 2006). Analysis of the H2B showed sequence
homology of carboxyl-terminal region among different Leishma-
nia species, ensuring cross-specific protection. A recent study
demonstrated that entire H2B protein is more efficient than its
amino- or carboxyl-terminal in inducing a dominant Th1 profile
that holds future against leishmaniasis (Meddeb-Garnaoui et al.,
2010). Considerable leishmanicidal properties (dose-dependent
killing promastigotes of L. amazonensis, L. major, L. braziliensis,
and L. mexicana) have also been demonstrated for histones H2A
and H2B (but not histone HI0) (Wang et al., 2011) which show
a new possibility of using these histone proteins for therapeutic
vaccinations against leishmaniasis.
Open reading frame (ORFF), is a single copy gene, located on
chromosome35 as a part of themultigene LD1 locus,preferentially
expressed in L. donovani amastigotes (Jain and Madhubala, 2008).
Purified recombinant ORFF protein has been partially protective
against L. donovani challenge in murine model (Tewary et al.,
2004b). More recently, ORFF expressed as a chimeric ubiquitin
conjugate was tested against antimony-sensitive and antimony-
resistant strains of L. donovani as a vaccine candidate. This study
demonstrated better protective efficacy of ubiquitin-conjugated
ORFF than unconjugated one against experimental VL (Sharma
and Madhubala, 2009). Several other subunit protein vaccines
have been tested against different forms of leishmaniasis with
varying success. These include dp72 (Jaffe et al., 1990; Aguilar-Be
et al., 2005), ribosomal P0 protein (Iborra et al., 2005),Leishmania
elongation factor 2 (LelF-2) (Kushawaha et al., 2011), amastigote
cysteine proteases (Zadeh-Vakili et al., 2004), F14 (Bhardwaj et al.,
2009), hydrophilic acylated surface protein B1 (HASPB1) (Stager
et al., 2000), etc. The observation that some individuals exposed
to uninfected sandfly mount a protective response to Leishmania
(Davies andMazloumiGavgani, 1999) has lead to vaccine attempts
designed against sandfly salivary proteins or insect gut antigens
that can protect from infection (Morris et al., 2001). Recently,
hamsters immunized with LMJ 19, a novel 11kDa protein from
Lutzomya longipalpis saliva, were reported to be protected against
VL (Gomes et al., 2008).
The use of synthetic peptide vaccines, particularly the T-cell
epitopes also opened an interesting avenue in Leishmania vaccine
since 1980s (Lamb et al., 1984; Jardimet al., 1990;Russo et al., 1993;
Spitzer et al., 1999). However, this enthusiasm has waned in recent
times due to inadequate memory response and inability of all
individuals to respond to the peptide, which needs to be resolved.
Contrary to defined single antigen, multicomponent or
polyprotein vaccines have been demonstrated to afford better pro-
tection against experimental VL. LEISH-F1 (formerly Leish111f),
consisting of three recombinant antigens: Leishmania elongation
initiation factor (LeIF), thiol-specific antioxidant (TSA), and L.
major stress-inducible protein-1 (LmSTI1) is such a polyprotein
vaccine that was able to confer protection against L. major (Skeiky
et al., 2002) and L. infantum (Coler et al., 2007). A crucial com-
ponent of LEISH-F1 vaccination is the selection of the adjuvant.
The vaccine remainedmost efficaciouswhen co-administeredwith
IL-12, as well as detoxified derivative of lipid A from lipopolysac-
charide (LPS) of Salmonella Minnesota, lipid A formulated with
squalene in a stable emulsion (MPL-SE). LEISH-F1+MPL-SE is
the only second-generation vaccine that successfully cleared the
clinical trial for safety and immunogenicity againstVL (Vélez et al.,
2009; Chakravarty et al., 2011).
Subunit vaccines based on recombinant proteins and syn-
thetic peptides are safe. However, they are poor generators of
cytotoxic T-cell (CTL) responses (Lima et al., 2004) and no sin-
gle antigen could confer complete protection. To overcome this
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Table 1 | Second-generation vaccine candidates tested against L. donovani.
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
FML Native antigen+Saponin Hamster L. donovani Protection Palatnik de Sousa et al.
(1994a)
FML Native antigen+Saponin Mouse L. donovani Protection Palatnik de Sousa et al.
(1994b)
FML Native antigen+Saponin/Aluminum
hydroxide
Mouse L. donovani Protection Santos et al. (1999)
FML Native antigen+ IL-12/BCG/saponin Mouse L. donovani Protection Santos et al. (2002)
FML Native antigen+Quill A Dog L. donovani Protection Borja-Cabrera et al. (2002)
FML Native antigen+Saponin Mouse L. donovani Protection Santos et al. (2002)
FML Native antigen+Saponin Mouse L. donovani Protection Palatnik de Sousa et al.
(2004)
LAg Native antigen entrapped in cationic
liposome
Mouse/Hamster L. donovani Protection Afrin and Ali (1997), Ali and
Afrin (1997)
LAg Native antigen entrapped in negatively
charged liposome
Mouse L. donovani Partial protection Afrin et al. (2000)
LAg Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Mazumder et al. (2004)
LAg Native antigen entrapped in liposomes Mouse L. donovani Protection Bhowmick et al. (2010)
LAg Native antigen+BCG/MPL/entrapped
in liposomes
Mouse L. donovani Protection Ravindran et al. (2010)
SLA Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick et al. (2007)
SLA Native antigen+non-coding pDNA
co-entrapped in cationic liposome
Mouse L. donovani Protection Mazumder et al. (2007)
SLA Native antigen entrapped in cationic
liposome+MPL
Mouse L. donovani Protection Ravindran et al. (2012)
gp36 Native antigen+Saponin Mouse L. donovani Protection Paraguai de Souza et al.
(2001)
SA Native antigen+CpG-ODN Mouse L. donovani Protection Tewary et al. (2004a)
LD 31, 51, 72, 91 Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick and Ali (2009)
gp70-2/dp72 Native antigen+Corynebacterium
parvum
Mouse L. donovani Partial protection Jaffe et al. (1990)
Hsp70+Hsp83 Native antigen+MPL/ALD Mouse L. donovani Protection Kaur et al. (2011b)
gp63+Hsp70 Native antigen Mouse L. donovani Protection Kaur et al. (2011a)
LPG Native antigen+BCG Mouse/Hamster L. donovani No protection Tonui et al. (2001)
78 kDa Native antigen Mouse L. donovani Protection Mukherjee et al. (2002)
78 kDa Native
antigen+MPL/ALD/liposome/FCA
Mouse L. donovani Protection Nagill and Kaur (2010)
dp72 Native antigen Mouse L. donovani/L. major Cross-protection Rachamim and Jaffe (1993)
gp63 Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick et al. (2008)
A2 Recombinant
antigen+Propionibacterium acnes
Mouse L. donovani Protection Ghosh et al. (2001b)
HASPB1 Recombinant antigen+ IL-12 Mouse L. donovani Protection Stager et al. (2000)
gp63 Recombinant antigen+S. typhimurium Mouse L. donovani/L. major Cross- protection McSorley et al. (1997)
gp63 Recombinant antigen entrapped in
cationic liposome+MPL-TDM
Mouse L. donovani Protection Mazumder et al. (2011a)
F14 Recombinant antigen+MPL Hamster L. donovani Protection Bhardwaj et al. (2009)
Leishmune Recombinant antigen Dog L. donovani Protection Nogueira et al. (2005)
Leishmune Recombinant antigen Dog L. donovani Partial protection Saraiva et al. (2006)
(Continued)
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Table 1 | Continued
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
ORFF+BT1 Recombinant antigen Mouse L. donovani Partial protection Dole et al. (2000)
ORFF Recombinant antigen+CpG-ODN Mouse L. donovani Partial protection Tewary et al. (2004b)
ORFF Recombinant antigen Mouse L. donovani Partial protection Tewary et al. (2005)
ORFF Recombinant antigen+ IL-12 DNA Mouse L. donovani Protection Tewary et al. (2005)
LdγGCS Recombinant antigen entrapped in NIV Mouse L. donovani Protection Henriquez et al. (2010)
LelF-2 Recombinant antigen Hamster L. donovani Protection Kushawaha et al. (2011)
BCG: Mycobacterium bovis Bacillus Calmette–Guerin; LPG, lipophosphoglycan; FML, fucose-mannose ligand; LdγGCS, L. donovani gamma-glutamyl cysteine syn-
thetase; LelF-2, L. donovani elongation factor-2; gp, glycoprotein; ORFF, open reading frame F; BT1, biopterin transporter; dp72, L. donovani promastigote antigen of
72 kDa; HASPB1, hydrophilic acylated surface protein B1; Hsp, heat-shock protein; LAg, leishmanial membrane antigen; NIV, non-ionic surfactant vesicle; CpG-ODN,
CpG oligodeoxynucleotides; ALD, autoclaved L. donovani.
inherent problem of subunit vaccines, several studies are being
carried out with promising adjuvants like Bacillus–Calmette–
Guerin (BCG), alum, saponin, liposomes, MPLA, and other TLR
ligands for vaccine success against VL (Bhowmick et al., 2008).
Long-term immunity generated by subcutaneous immunization
of liposomal soluble leishmanial antigen (SLA) with MPL-TDM
(monophosphoryl lipid–trehalose dicorynomycolate) in BALB/c
mice largely depends on high IFN-γ and CD8+ T cells, along
with downregulation of IL-4 (Ravindran et al., 2012). RAPSODI, a
human-compatible second-generation vaccine is currently under-
going preclinical trial heading toward a pan-Leishmania vaccine
(Rapsodi against leishmaniasis2; accessed 2 January 2012). Based
on the most immunodominant antigen, promastigote surface
antigen (PSA) expressed in L. tarentolae system (LEXSY, Jena Bio-
science), RAPSODI holds a promising future for a cross-protective
Leishmania vaccine.
Dendritic cell (DC) – based vaccines
DCs are a class of specialized APCs that orchestrate both innate
and acquired immunity. TLR:PAMP interaction leads to matu-
ration of DCs lying in the interface external environment and
mucosal surface, inducing the expression of co-stimulatory mole-
cules CD40, CD80, and CD86 required for T-cell activation. The
secreted cytokines, namely IFNs and IL-12 drive the T-cell differ-
entiation toward CD4+ Th1 or CD8+ CTL response. DC-based
anti-leishmanial vaccines comprise a novel yet nascent strategy for
long-lasting immunity (Moll and Berberich, 2001; Donaghy et al.,
2010). Generation of parasite-specific Th1 biased long-term pro-
tection by plasmacytoid DC-based vaccination against L. major
(Tsagozis et al., 2004; Remer et al., 2007) provided the thrust for
targeting DC vaccines againstVL. Adoptive transfer of DCs pulsed
ex vivo with soluble L. donovani Ags (SLDA) to naive mice induced
theAg-specific production of IFN-γ. However, complete clearance
of parasites from liver was attained only after IL-12-transduction
of SLDA-pulsed DCs (Ahuja et al., 1999). This outlines the impor-
tance of paracrine delivery of IL-12 for DC-based vaccination.
In a recent study, bone marrow-derived DCs (BM-DCs) pulsed
ex vivo with the peptide 12-31aa portion of kinetoplastid mem-
brane protein, KMP-11 (12-31aa) and CpG-ODN was protective
2http://www.fp7-rapsodi.eu/
in a murine model of VL (Agallou et al., 2011). In another study,
combination therapy using SLDA-pulsed syngenic bone marrow-
derived DC and antimony-based chemotherapy could cure estab-
lishedmurineVL viaCD4+ T cell dependent Th1 response (Ghosh
et al., 2003). Similar protective effects of microbial antigen-loaded
DCs have also been reported for other pathogens (Bourguin et al.,
1998; George-Chandy et al., 2001; McShane et al., 2002) and
antitumour immunity (Kobukai et al., 2011). Another interest-
ing approach has implemented hybrid cell vaccination therapy
using L. donovani kinetoplastid membrane protein-11 (KMP-
11)-transfected bone marrow-derived macrophages from BALB/c
mice with allogeneic bone marrow-derived DCs from C57BL/6
mice to resolve infection by establishing strong antigen-specific
CD8+ CTL response (Basu et al., 2007). DCs have been pro-
posed to play a critical role as immunomodulators in vaccination
and therapy, and are therefore an important tool for prophylactic
vaccination against serious infections. Integrating DC vaccina-
tions with standard anti-leishmanial chemotherapy could thus
be highly beneficial for therapeutic vaccination against VL. Nev-
ertheless, this strategy has its limitations. Large-scale generation
of leishmanial Ag-pulsed and/or cytokine-transduced autologous
DC vaccine seems laborious and expensive, and could thus possi-
bly limit its use in developing countries. Moreover, the choice of
DC subtype, antigen-loading strategy, maturational status, route
and frequency of immunization, and adjuvant cytokines all affect
the performance of a DC vaccine.
THIRD GENERATION VACCINES
Genetic vaccination has been a better and flexible strategic alter-
native for inducing stronger Th1 biased immune response than
their recombinant protein counterparts which often suffer from
poor immunogenicity due to alerted pathoantigenic epitopes
(Gurunathan et al., 1998; Rafati et al., 2006). An important feature
of DNA vaccination is the induction of CD8+ cytotoxic T cells
along with sufficient CD4+ T cell and humoral response. This
contributes to cytolysis of parasite-infected cells by CD8+ T cells
and increased IFN-γ secretion for efficient leishmanicidal activ-
ity (Aguilar-Be et al., 2005; Carter et al., 2007). However, priming
and expansion of CD8+ T cells solely depends upon CD4+ T cells
which is vital for initiation and maintenance of immune mem-
ory (Bourgeois et al., 2002; Janssen et al., 2003). This concept of
Th cell help for CTL response has led to further improvement
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of DNA vaccine constructs and adjuvant strategies over time. In
addition to codon-optimized vectors, fusion of immune modula-
tors (like CpG motifs, GM-CSF, Flt3 ligands, and cytokine genes)
and novel delivery systems like electroporation, and the concept
of heterologous prime-boosting have been employed successfully
against Leishmania and several other pathogens. gp63,Leishmania
analog of the receptor kinase C (LACK) and ORFF are the most
extensively studied DNA vaccine candidates against VL till date
(Table 2). Vaccination with a plasmid encoding LACK gene with
or without co-administration of 1L-12 resulted in robust, long-
lasting protection in mice against L. major (Gurunathan et al.,
1997, 1998; Stobie et al., 2000). Intranasal immunization with
plasmid carrying LACK has also been protective against L. cha-
gasi both in mice (Gomes et al., 2007) and hamster model (DE
Oliveira Gomes et al., 2011) of VL. In contrast to LACK, which
failed to protect against L. donovani (Melby et al., 2001b), prim-
ing with gp63 DNA with protein boost afforded robust, long-term
protection in susceptible BALB/c mice (Mazumder et al., 2011b).
Similarly, ORFF (Tewary et al., 2005), KMP-11 (Basu et al., 2005),
and cysteine proteases (Rafati et al., 2006) have been protective
as DNA vaccines against different Leishmania species. Protec-
tion was significantly improved when vaccines were composed of
a cocktail of plasmids expressing immunodominant Leishmania
genes. Accordingly, vaccination of mice with cocktail of plasmids
harboring gp63 andHsp70 genes elicited robust protection against
L. donovani with enhanced IFN-γ and IL-2 driving toward an
excellentTh1biased immune response (Kaur et al., 2011a). Further
studies are required in higher animal models for such promising
combination vaccines to ensure protection before they are finally
evaluated in patients with VL. An interesting approach based on
cDNA libraries has been adopted to identify protective L. donovani
antigens through cDNA immunizations (Melby et al., 2000). Plas-
mid DNAs isolated from several cDNA sublibraries constructed
from amastigote-derived RNA have been screened by immuniza-
tionof BALB/cmice. Several groups of cDNAthat conferred in vivo
protection against subsequent L. donovani challenge have been
identified by this technique.
Several lines of evidence suggest a central role of DCs
in antigen presentation after DNA vaccination (Corr et al.,
1996; Akbari et al., 1999) which explains the success of DC-
targeted adjuvants like GM-CSF, TLRs, and Flt3 ligands when
co-administered with plasmid DNA (Encke et al., 2006). LEISHD-
NAVAX, based on MIDGE vector, developed by Mologen AG
(Berlin, Germany) is presently undergoing preclinical trials in
Europe, against visceral and cutaneous forms of leishmaniasis,
along with a double stem loop immunomodulator (DSLIM)
Table 2 |Third generation vaccine candidates for L. donovani.
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
L. DONOVANI -DERIVEDANTIGENSTESTEDAGAINST L. DONOVANI
p36 LACK DNA vaccine+ IL-12 Mouse L. donovani No protection Melby et al. (2001b)
A2 DNA vaccine Mouse L. donovani Protection Ghosh et al. (2001a)
A2 Expressed in Lactococcus
lactis
Mouse L. donovani Protection Yam et al. (2011)
ORFF DNA vaccine Mouse L. donovani Partial protection Sukumaran et al. (2003)
ORFF-HPB DNA vaccine+ recombinant
protein
Mouse L. donovani Protection Tewary et al. (2005)
ORFF Ubiquitin conjugated DNA
vaccine
Mouse L. donovani Protection Sharma and Madhubala
(2009)
KMP-11 DNA vaccine Hamster L. donovani Protection Basu et al. (2005)
KMP-11 DNA vaccine+ IL-12 Mouse L. donovani, L. major Cross-protection Bhaumik et al. (2009)
γ GCS DNA vaccine Mouse L. donovani Protection Carter et al. (2007)
H2A,H2B, H3, H4, LACK Multiantigen DNA vaccine Dog L. donovani Partial protection Saldarriaga et al. (2006)
PPG-N-terminal domain DNA vaccine Hamster L. donovani Protection Samant et al. (2009)
gp63/polytope DNA vaccine/polytope/polytope
fused with hsp70
Mouse L. donovani Protection Sachdeva et al. (2009)
P1-HPB DNA vaccine+ recombinant
protein
Hamster L. donovani Protection Masih et al. (2011)
gp63-HPB DNA vaccine+ recombinant
protein+CpG-ODN
Mouse L. donovani, L. major Cross-protection Mazumder et al. (2011b)
L. DONOVANI -DERIVEDANTIGENSTESTEDAGAINST OTHER LEISHMANIA SPECIES
NH36 DNA vaccine Mouse L. chagasi, L. mexicana Cross-protection Aguilar-Be et al. (2005)
NH36 DNA vaccine Mouse L. chagasi Protection Gamboa-León et al. (2006)
A2 Expressed in adenovirus Mouse L. chagasi Protection Resende et al. (2008)
A2 Expressed in L. tarentolae Mouse L. infantum Protection Mizbani et al. (2009)
NH36, nucleoside hydrolase 36; HPB, heterologous prime-boost; KMP-11, kinetoplastid membrane protein-11; LACK, Leishmania analog of the receptors of activated
C kinase; PPG, proteophosphoglycan.
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adjuvant [Development of aDNAvaccine forVL: LEISHDNAVAX.
European Commission Research-Health;3 (accessed 2 January
2012)]. This multicomponent vaccine with three to four known
immunodominant leishmanial antigens holds a great therapeutic
and prophylactic potential against VL. Finally, safety issues must
be ensured during these early steps of DNA vaccine development
for human acceptance.
VL VACCINE DEVELOPMENT: NEW STRATEGIES
GENETICALLY ALTERED LIVE-ATTENUATED VACCINE
Vaccinationwith geneticallymodified Leishmania parasite is based
on decoupling virulence for induction of protective immunity.
This generally involves targeted disruption of virulence or essential
leishmanial genes resulting in mutated parasites lacking viru-
lence. These mutants closely mimic the natural course of infec-
tion through PAMPs required for adequate stimulation of innate
immunity for long-term immune memory. Such live-attenuated
vaccines have been successfully used against several viral and
bacterial pathogens (Nakhasi et al., 1989; Larsen et al., 2009).
Despite several attempts, very limited numbers of genetically
modified live-attenuated forms of L. donovani exist as vaccine can-
didates. Recently, L. donovani centrin null mutants (Ld Cen−/−)
have been reported to protect BALB/c mice and Syrian hamsters
against homologous as well as heterologous infectious challenge
(Selvapandiyan et al., 2009). Immune protection upon 10 week
post-virulent challenge correlated with Th1 biased response with
significant increase in IFN-γ, IL-12, and TNF producing T cells
that significantly lowered the parasite burden in spleen along
with complete clearance of parasites in liver. Similar Th1 biased
protection has been shown in mice immunized with L. dono-
vani biopterin transporter null mutant (BT1−/−) (Papadopoulou
et al., 2002) and silent information regulatory 2 single-knock out
mutants (Li SIR2±) of L. infantum against virulent challenge
(Silvestre et al., 2007). Similarly, cytochrome C oxidase com-
ponent p27 null mutants (Ld p27−/−) of L. donovani showed
less virulence both in human macrophages and in BALB/c mice
(Dey et al., 2010) which may be explored further. More recently,
a preliminary evaluation using L. infantum heat-shock protein
(HSP70-II) null mutant seems promising in inducing protection
in L. major-BALB/c infection model (Carrión et al., 2011).
An interestingly different approach using non-pathogenic
species like L. tarentolae as live vaccine showed enhanced anti-
gen presentation and potent Th1 response against L. donovani
challenge in BALB/c mice (Breton et al., 2005). Further refine-
ment of this approach using recombinant L. tarentolae expressing
L. donovani A2 antigen was cross-protective against both L. infan-
tum (Mizbani et al., 2009, 2011) and L. donovani (Yam et al., 2011).
Overall, the use of live, non-pathogenic/genetically engineered
Leishmania seems to be the most promising strategic alternative
against VL. However, the underlying risk of reversion to viru-
lence chiefly in immunocompromised individuals is an important
limitation for their large-scale use.Additionally,presence of antibi-
otic resistant genes in attenuated parasite strains hinders their
use in clinical studies. Moreover, safety blocking of vaccine strain
3http://ec.europa.eu/research/health/infectious-diseases/neglected-diseases/
projects/006 en.html
transmissibility by sandfly vector is another important issue that
needs clarification.
PROTEOMIC APPROACHES
Proteomics, being widely applied in studying Leishmania spp., is a
powerful tool for elucidating bothmolecular pathology andmech-
anistic searching of novel vaccine targets often missed following
conventional techniques. Current immunoproteomics using two-
dimensional gel electrophoresis (2-DE) and matrix-assisted laser
desorption/ionizationmass spectrometry (MALDI-MS) approach
focuses on identification and evaluation of responses to para-
site T-cell epitopes as putative vaccine targets. Recent proteome-
serological methodology using 2-D Western blot analyses from
clinical isolates and sera of Indian VL patients have led to detec-
tion of 330 different immunogenic antigens (Forgber et al., 2006).
Another systematic study detected a total of 33 T-cell stimulat-
ing antigens from soluble proteins of L. donovani clinical isolate,
M.W. ranging from 68 to 97.4 kDa (Gupta et al., 2007) that showed
significant prophylactic potential against L. donovani challenge in
hamster model of VL (Garg et al., 2006). Availability of anno-
tated 32.8-Mb sequenced genomewith 8272 protein coding genes4
of L. major permits identification of all potential protein prod-
ucts precisely outlining heterogeneity of complex host responses
to leishmanial antigenic variation, and will be useful in rational
designing of vaccine. Additional proteomic approaches analyzing
sandfly salivary components have identified a large prospective
candidate repertoire for vaccine development against leishmania-
sis (Titus and Ribeiro, 1988; Gillespie et al., 2000; Valenzuela et al.,
2004).
However, the field of proteomics in Leishmania mostly lim-
its itself to cytosolic proteins thereby excluding many pathogenic
extracellular membrane proteins due to difficulties in solubilizing
their hydrophobic transmembrane domains. Also, the approach
remains insufficient for identification of protein subsets actually
being expressed in parasites. Combining biological functions of
identified proteins via activity-based techniques would accelerate
this process of post-genomic vaccine research in future.
SUBTRACTIVE GENOMICS
A very recently adopted methodology is based on subtraction
of sequence between host and parasite proteome. Availability of
whole genome sequence for human and pathogenic microbes has
been utilized to find non-human homologous vaccine and ther-
apeutic targets against Helicobacter pylori (Huynen et al., 1998;
Dutta et al., 2006), Pseudomonas aeruginosa (Sakharkar et al.,
2004; Perumal et al., 2007), Mycobacterium pneumonia (Gupta
et al., 2010), Borrelia burgdorferi (Madagi et al., 2011), Chlamy-
dia trachomatis (Praveena et al., 2011) as well as L. donovani
(Mandage and Wadnerkar, 2010) that are currently facing the
problems of drug resistance or absence of vaccines. Thus sorted
key pathogenic proteins essential for parasite survival but non-
homologous to human host, are subsequently checked for their
cellular localization within the pathogen, exo-membrane topol-
ogy and role in metabolic pathways to be used for drug or
4http//www. genedb.org/leish/index.jsp
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prophylactic targets. Usually, conserved secreted and membrane
proteins from pathogens are selected to design novel vaccines
(Dutta et al., 2006; Barh et al., 2010). A preliminary work based on
computational subtractive genomics has identified protein kinase,
adenylate kinase and MAP kinase homolog of L. donovani for
regulating normal cell cycle and differentiation of the parasite
(Mandage and Wadnerkar, 2010). The experimental evaluation
of such vaccine targets is required to validate their prophylactic
potential. Further prediction of functional sites and exploration
of Leishmania proteome are required to get the full benefit of
this approach for a cross-protective VL vaccine. Moreover, it is
advisable to consider all the pathogenic strains undertaking in sil-
ico mutagenesis approach and pangenomics data base, for further
improvement of this basic strategy.
CHALLENGES AND FUTURE PROSPECT
A major challenge in vaccination against Leishmania and several
other intracellular pathogens is the requirement of strong cell-
mediated immune response in mediating protection. Most of the
licensed prophylactic vaccines for human use rely completely on
humoral response which have limited efficacy against Leishma-
nia. Although adjuvants like alum, AS04 (composed of MPLA
adsorbed to alum), MF59 and AS03 (oil-in-water emulsion) are
approved for human use, inability to trigger robust T-cell response
remains a potential short-coming of killed/subunit vaccines. None
of the Leishmania vaccines reaching clinical trials could show ade-
quate efficacy due to poor CD8+ T-cell responses arising from
inefficient cross-presentation. Live-attenuated vaccines are advan-
tageous in generating durable cellular (both CD4+ and CD8+)
response mostly due to temporary parasite persistence and proper
antigen presentation. However, they are largely precluded due to
safety reasons. Although, in the current scenario, a plasmid DNA
vaccine following heterologous prime-boost strategy seems to be
a promising prophylactic choice for generating robust cellular and
humoral response, they are largely tempered by chances of chronic
inflammation, autoantibody generation and systemic lupus ery-
thematosus (SLE), or integration into host genome thatmay either
activate oncogenes or deactivate tumor suppressor genes. Further,
optimization in terms of magnitude of T-cell response and safety
is warranted for genetic vaccinations before human administra-
tion. Additionally, most of the commonly used immunological
assays for evaluating adaptive immunity in vaccinated animals are
often insufficient and need to be revitalized. Adoption of newer
sophisticated technologies like multiparametric flow cytometry
for evaluating magnitude and quality of multifunctional T cells
simultaneously producing IFN-γ, IL-2, IL-10, and TNF-α can be
acquired for better correlation with diverse immunopathogen-
esis and protection (Selvapandiyan et al., 2009; Macedo et al.,
2012). Similarly, parasite quantification in challenged animals by
real-time PCR can help quantify as little as 0.1 parasites thereby
improving the accuracy of detection compared to conventional
microscopic counting of organ smear impressions and limiting
dilution assay (Nicolas et al., 2002).
Today’s Leishmania vaccine research is focused upon bridging
the common cellular and molecular components of different but
interdependent systems of innate and adaptive immunity by cer-
tain immunomodulators to raise highly integrated defense against
the parasites. Although all new vaccine approaches may not suc-
ceed in inducing sustained life-long immunity againstVL, a short-
termTh1 biased responsemay also be appreciated for its therapeu-
tic prospects. Interestingly, cationic liposomes alone can stimulate
DCs with upregulation of CD80 and CD86 co-stimulatory mol-
ecules to generate humoral as well as CD4+ and CD8+ T-cell
response resulting in activation of MHC-II and MHC-I path-
ways for antigen presentation. Formulating these cationic vesi-
cles with lipid -based TLR ligands like MPL, imiquimods, etc.
can be safe, immensely potent adjuvants against VL, for stronger
combined CTL and antibody response. Moreover, the immuno-
logical paradigm governing natural resistance to L. donovani in
certain individuals from Indian endemic pockets of VL remains
unexplored, which can be immensely informative for vaccine
design. In conclusion, correct orientations of innate biology and
adjuvant research fine tuned with emerging fields of immuno-
proteomics, Leishmania genome mining and system biology can
lead to absolute prophylactic anti-leishmanial vaccine in the near
future.
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